Novo Nordisk A/S
NVO
ISIN null / Valor 461641
Novo Nordisk A/S
UMushroom community rating:
About company
Novo Nordisk A/S is a Danish multinational pharmaceutical company focused principally on diabetes care and related metabolic disorders, developing, manufacturing and commercializing medicines and delivery devices—most prominently insulin and GLP‑1 receptor agonists used in type 2 diabetes and obesity treatment—and it also markets therapies for haemophilia, growth disorders and hormone replacement. The company combines clinical research and development with large‑scale manufacturing and worldwide commercial operations and is publicly listed on the Copenhagen stock exchange. Internally, Novo Nordisk operates under corporate conduct frameworks (OneCode and the Novo Nordisk Way) that define expected standards of behaviour and decision‑making for employees.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (20.10.2025):
In the first half of 2025, Novo Nordisk A/S reported strong financial performance with net sales increasing by 16% in Danish kroner to DKK 154.9 billion and operating profit rising by 25% to DKK 72.2 billion. Despite these robust results, the company has adjusted its full-year outlook due to slower growth expectations in the second half of the year.
Sales Growth
Net sales grew by 16% in Danish kroner and 18% at constant exchange rates, reaching DKK 154.9 billion for H1 2025. US operations saw a 16% increase in sales, while International Operations experienced a similar growth rate of 16% in Danish kroner.
Operating Profit
Operating profit surged by 25% in Danish kroner to DKK 72.2 billion, representing a 29% increase at constant exchange rates. This growth underscores the company's effective cost management and expanding revenue streams.
Segment Performance
Sales within Diabetes and Obesity care rose by 16% to DKK 145.4 billion, driven by a 56% increase in Obesity care and an 8% growth in GLP-1 diabetes sales. Rare disease sales also saw a 14% uptick.
Research and Development
In R&D, Novo Nordisk is advancing new treatments, including subcutaneous and oral amycretin into phase 3 development for weight management. Additionally, the REDEFINE 11 study has been initiated to explore the efficacy and safety of CagriSema, and a higher dose of Wegovy® has been submitted for EU regulatory approval.
2025 Outlook
The company now projects sales growth of 8-14% and operating profit growth of 10-16% at constant exchange rates for the full year 2025. The revised outlook reflects lower growth expectations for the second half of the year due to factors such as increased competition and slower market expansion.
Leadership Changes
Effective August 7, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as CEO. Additionally, Emil Kongshøj Larsen will take over as Executive Vice President of International Operations, and Martin Holst Lange will lead the consolidated R&D areas.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
160447 M
Market cap (USD)
18,985,250
Daily traded volume (Shares)
86.86 / 85.69
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Atul Kanodia
Jules Robin
Aaron Lal
EQUITIES OF THE SAME SECTOR
